Director-General's Office

Information Session on the UN Inter Agency Coordination Group on Antimicrobial Resistance

Dr Tedros Adhanom Ghebreyesus
Director-General

Geneva, Switzerland
1 October 2018

Excellencies, distinguished guests, ladies and gentlemen,

A very warm welcome to WHO. It’s great to have you here as always. As you know, this is a very important subject matter to all of us. I’m glad that we are fighting AMR together.

As you know, addressing AMR is a key priority for WHO. It’s one of five platforms or initiatives in our five-year strategic plan, which was approved by the World Health Assembly earlier this year. The investment case we launched two weeks ago also talks about the importance of a properly resourced WHO for tackling antimicrobial resistance.

It says clearly that WHO will strengthen its collaboration and action with all sectors and the tripartite of WHO, FAO and OIE in a One Health approach. We’re also recognising UN Environment’s role in addressing the environmental elements of antimicrobial resistance, and UNEP will join the tripartite relationship we have.

Just a couple of weeks ago we met in Rome to formalize the details of a global work plan to ensure the implementation of the memorandum of understanding we signed as tripartite organisations.

We’re delighted to have countries and partners here to discuss the draft global framework for development and stewardship to combat AMR.

Our aim here today is to kickstart the process of fostering a global approach to developing and using antimicrobials more efficiently to safeguard them for future generations.

The IACG has a vital role to play in developing and advising that approach for the future.

In May next year, the IACG will deliver its recommendations to the UN Secretary-General, for subsequent consideration at the UN General Assembly in 2019.

AMR is a unique, complex problem. To address it we need innovative, disruptive and breakthrough solutions.

AMR poses a great threat to achieving universal health coverage and the Sustainable Development Goals.

I am personally committed to the urgency of tackling AMR.

We are currently harmonizing AMR efforts in Headquarters to expedite efficiency and results.

We are leading in areas of generating strategic information on AMR, setting norms and standards, and providing technical support.

I am pleased today to have Sweden and Ghana giving special remarks on the IACG and the way forward. We need the engagement of all Member States in tackling the AMR challenge.

My hope is that together we take full advantage of the IACG so that we can continue relying on antimicrobials for health in the future.

I thank you.